Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
APC Anti-Human CD152 (CTLA-4) (BNI3) Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| FC |
|---|---|
| Isotype | Mouse IgG2a, kappa |
| Concentration | 5 uL (0.125 ug)/test |
| Reactivity | Human |
| Formulation | 10 mM NaH2PO4, 150 mM NaCl, 0.09% NaN3, 0.1% gelatin, pH7.2 |
| Host | Mouse |
| Gene ID | 1493 |
|---|---|
| Gene Name | CTLA4 |
| Alternative Name(s) | Cytotoxic T-Lymphocyte Antigen 4, CTLA4 |
| Format | APC |
| Preparation | This monoclonal antibody was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation. It is recommended to store the product undiluted at 4°C, and protected from prolonged exposure to light. Do not freeze. |
| Application Notes | This antibody preparation has been pre-titrated and quality-tested for flow cytometry using an appropriate cell type. The antibody has been diluted for use at 5 uL per test, defined as the amount of antibody that will stain a cell sample in a final volume of approximately 100 uL. The number of cells within a sample should be determined empirically, but typically ranges between 1x10e5 to 1x10e8 cells. |
| Storage Conditions | 2-8°C protected from light |
Moreno-Fernandez ME, Rueda CM, Rusie LK, and Chougnet CA. 2011. Blood. 117: 5372-5380. (in vitro blocking)
Schonfeld D, Matschiner G, Chatwell L, Trentmann S, Gille H, Hulsmeyer M, Brown N, Kaye PM, Schlehuber S, Hohlbaum AM and Skerra A. 2009. 106: 8198-8203. (Immunohistochemistry – frozen tissue)
Rivas MN, Weatherly K, Hazzan M, Vokaer B, Dremier S, Gaudray F, Goldman M, Salmon I, and Braun MY. 2009. 183:4284-4291. (in vitro blocking)
Bonzheim I, Geissinger E, Tinguely M, Roth S, Grieb T, Reimer P, Wilhelm M, Rosenwald A, Muller-Hermelink HK, and Rudiger T. 2008. Am. J. Clin. Pathol. 130: 613-619. (Immunohistochemistry – paraffin embedded tissue; Immunofluorescence microscopy – frozen tissue)
Young NT, Waller ECP, Patel R, Roghanian A, Austyn JM, and Trowsdale J. 2008. 111: 3090-3096. (in vitro activation)
Wei B, da Rocha Dias S, Wang H and Rudd CE. 2007. J. Immunol. 179: 400-408. (in vitro activation)
Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J and Enk AH. 2001. J. Exp. Med. 193: 1285-1294 (in vitro blocking)
Oaks MK and Hallett KM. 2000. J. Immunol. 164: 5015-5018. (Immunoprecipitation; EIA – plate coating)
Provided below are standard protocols that you may find useful for product applications.
Background
The BNI3 antibody is specific for human CD152, commonly known as CTLA-4, a 33-37 kDa protein expressed as a homodimer on the surface of activated T and B cells, and on thymocytes. CTLA-4 is structurally similar, yet functionally disparate, to the T cell co-stimulatory molecule CD28. Both CTLA-4 and CD28 interact with the co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells, with CTLA-4 displaying a higher avidity than CD28. While CD28 typically delivers a potent co-stimulatory signal in support of T cell activation, CTLA-4 appears to act as a negative regulator of T cell activation and may contribute to the suppressor function of Treg cells.
CTLA-4 proteins may be initially sequestered within Golgi vesicles, from which they can be transferred to and from the cell surface, a mechanism by which Treg cells can selectively impart suppressive functions. The BNI3 antibody may be used for flow cytometric analysis of intracellular or surface CTLA-4 expression, and is also widely used for neutralization of CTLA-4 when expressed at the cell surface. The BNI3 antibody is reported to be cross-reactive with Baboon, Cynomolgus and Rhesus CTLA-4.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
